Belgian Life Science Investor Exceeds Expectations With New €125m Fund

Fund+ has beaten its €100m target to raise €125m for life science investment in Europe – making it the largest private biotech fund in Belgium.

SC1610_Town of leuven_1200x675
Based in Leuven, Fund+ will focus on life science investments in Belgium • Source: Shutterstock/gringos4

Following a recent capital increase Fund+ now has €125m to spend on drug developers, medtech firms and in vitro diagnostic research in Belgium – with a big dream of creating sustainable shareholder value and a leadership position for the Belgian life sciences sector, while also generating a beneficial societal impact.

The fund, which launched in 2015, has made six investments so far, most of which target the busy pipeline areas...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.